ReviewJournal of translational medicine2026
5-mC RNA methylation: a key regulator in cancer development and treatment.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background5-methylcytosine (5-mC) RNA methylation is a prevalent post-transcriptional modification affecting both coding and non-coding RNAs. 5-mC methylation can regulate the expression level of relevant genes and biological processes by affecting RNA stability, translation efficiency, spatial structure, protein interactions, and other processes. Emerging evidence highlights its critical role in cancer biology. MAIN BODY: Abnormal changes in 5-mC methylation lead to aberrant expression of oncogenes or inactivation of suppressor genes, which in turn affects the growth and differentiation of cells. High 5-mC methylation tends to promote malignant cancer progression through pathways such as carcinogenesis, proliferation, metastasis, metabolic reprogramming, immunosuppression and drug resistance. These effects are mediated through RNA methylation writers, readers, and erasers. The multiple regulatory roles of 5-mC methylation modification in cancer development and progression make it an important direction for cancer therapy researches.
conclusion5-mC methylation is expected to be used to predict disease progression and guide therapeutic regimens, and is an important target for the development of novel anticancer therapies with great clinical translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.